Australia markets closed

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.06-0.08 (-1.59%)
As of 02:37PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.14
Open5.21
Bid3.76 x 200
Ask6.57 x 200
Day's range5.05 - 5.25
52-week range1.86 - 9.01
Volume5,111
Avg. volume14,765
Market cap13.113M
Beta (5Y monthly)1.02
PE ratio (TTM)N/A
EPS (TTM)-236.13
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.00
  • Insider Monkey

    11 Best ASX Stocks To Buy Now

    In this piece, we will take a look at the 11 best ASX stocks to buy now. If you want to skip our introduction to the Australian stock market, then you can take a look at the 5 Best ASX Stocks To Buy Now. With a market capitalization of $1.5 trillion, the Australian stock exchange, […]

  • GlobeNewswire

    Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

    -First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- -Second Subject Scheduled to Receive BB-301 in February 2024- -23 Subjects Enrolled into the Oculopharyngeal Muscular Dystrophy Natural History Study with Multiple Subjects Eligible for entry into the Phase 1b/2a Clinical Treatment Study in 2024- HAYWARD, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Benite

  • GlobeNewswire

    Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

    Announcement marks the initiation of the first clinical trial conducted in human subjects employing Benitec’s “Silence and Replace” DNA-directed RNA interference gene therapy platformHAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, tod